Rebecca Araujo

DocwireNews

Researchers from the University of British Columbia and Vancouver General Hospital evaluated incidence and risk factors for mortality within one year of autologous hematopoietic cell transplantation (AHCT) for the treatment of multiple myeloma (MM).For this study, which was published in <a href="https://linkinghub.elsevier.com/retrieve/pii/S2152265021000872">Clinical Lymphoma, Myeloma, &amp; Leukemia</a>, the investigators retroactively reviewed rates of early mortality, defined as death within one year, among 962 patients who underwent <a href="https://www.docwirenews.com/docwire-pick/dr-hari-discusses-upfront-ahct-for-multiple-myeloma/">AHCT</a> between 2007 and 2019. The overall mortality rate was 4.3 (n=41). Patients who died were matched for age, sex, and year of transplant with surviving controls.Most patients (97.6%) who had early mortality received at least one novel agent, and 80.5% of these patients received second-line chemotherapy. Upon multivariate analysis, comorbidities including anemia and hypercalcemia were associated with early mortality. High-risk cytogenetics and elevated lactate dehydrogenase also correlated with death within one year.&ldquo;Clinical parameters reflecting disease burden, as well as high-risk cytogenetics, are associated with early mortality post-AHCT,&rdquo; wrote the authors in conclusion. &ldquo;These patients have a dismal overall survival despite significant advances in treatment of patients with relapsed or refractory MM. Further study of these ultra-high-risk patients is required to improve disease management and may give further insights into the biology of relapse and resistance in MM.&rdquo;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Risk Factors for Early Mortality After AHCT in Multiple Myeloma

Oncology

Researchers from the University of British Columbia and Vancouver General Hospital evaluated incidence and risk factors for mortality within one year of autologous ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe